The US Food and Drug Administration (FDA) has approved AbbVie’s Imbruvica (ibrutinib) for the treatment of patients with relapsed / refractory (R/R) marginal zone lymphoma (MZL).

The indication is approved under accelerated approval, which is based on overall response rate (ORR).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Pharmacyclics, an AbbVie company, and Janssen Biotech have jointly developed and commercialised Imbruvica.

Pharmacyclics early development and immunotherapy head Darrin Beaupre said: "The FDA approval of imbruvica for relapsed / refractory marginal zone lymphoma is significant, and we are proud of the culmination of this extensive clinical research programme, representing the first approved treatment specifically for patients with this rare type of non-Hodgkin's lymphoma.

"This milestone marks the fifth patient population for whom imbruvica is now approved and broadens the number of patients who may be treated with the medication."

See Also:

"This milestone marks the fifth patient population for whom imbruvica is now approved and broadens the number of patients who may be treated with the medication."

The approval in MZL is based on data from the Phase II single-arm PCYC-1121 study, which evaluated the safety of the indication in MZL patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Memorial Sloan Kettering Cancer Center hematologic oncologist Ariela Noy said: "In the Phase II trial, imbruvica demonstrated impressive response rates and duration of response in relapsed / refractory marginal zone lymphoma patients.

"The haematology-oncology community welcomes a new option like imbruvica, which helps fill a significant treatment gap for previously treated MZL patients who are in need of non-chemotherapy options."

Imbruvica is now approved for the treatment of patients with MZL who require systemic therapy and have received at least one prior anti-CD20-based therapy.

The slow-growing B-cell lymphoma MZL arises from white blood cells (lymphocytes) at the edges of lymphoid tissue.